J.G.M. Klijn - Concepedia

Author

J.G.M. Klijn

Rotterdam University of Applied Sciences

Also Known As

HT Mouridsen, J G Klijn, J G M Klijn, J KLIJN, J Klijn, J. G. Klijn, J. G. M. KLIJN, J. G. M. Klijn, J. Klijn, J.G. Klijn

150

Publications

10.9K

Citations

H-Index

Concepts

All Affiliations

Rotterdam University of Applied Sciences Erasmus University Rotterdam Erasmus MC Erasmus MC Cancer Institute Leiden University Medical Center

About

J.G.M. Klijn is an author at Rotterdam University of Applied Sciences specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	38	56	7.7K
2	Health Sciences	5	5	259
3	Nursing	2	2	59
4	Engineering	1	1	1.2K
5	Natural Sciences	1	1	98

J.G.M. Klijn

Publications

10.3K

Citations

H-Index

Page 1

	Year	Citations
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial M Baum, Aman U. Budzar, J Cuzick, The Lancet Breast OncologyEarly Breast CancerMedicinePharmacologyGynecology	2002	2K
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer Yongyu Wang, J.G.M. Klijn, Y ZHANG, The Lancet Radiation OncologyBreast OncologyOncologyEngineeringDistant Metastasis	2005	1.2K
Multifactorial Analysis of Differences Between Sporadic Breast Cancers and Cancers Involving BRCA1 and BRCA2 Mutations Sunil R. Lakhani, J Jacquemier, J P Sloane, JNCI Journal of the National Cancer Institute	1998	695
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. John A. Foekens, Harry A. Peters, Maxime P. Look, PubMed Tumor BiologyBreast OncologyOncologyPlasminogen ActivationBreast Cancer Patients	2000	429
Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over Robert Paridaens, Laura Biganzoli, P.F. Bruning, Journal of Clinical Oncology	2000	355
Effectiveness of Breast Cancer Surveillance in <i> BRCA1/2</i> Gene Mutation Carriers and Women With High Familial Risk Cecile T.M. Brekelmans, Caroline Seynaeve, C.C.M. Bartels, Journal of Clinical Oncology Breast OncologyGeneticsEpidemiology Of CancerGenetic EpidemiologyOncology	2001	308
Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation E.J. Meijers-Heijboer, L.C. Verhoog, CTM Brekelmans, The Lancet Genetic TestingGenetic DisorderGeneticsPathologyProphylactic Surgery	2000	306
Somatostatin receptors in human endocrine tumors. J.C. Reubi, R. Maurer, Klaus von Werder, PubMed Endocrine OncologySpecific Somatostatin ReceptorsMedicineNonpituitary TumorsSomatostatin Receptors	1987	253
Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases Cecile T.M. Brekelmans, Madeleine M.A. Tilanus‐Linthorst, Caroline Seynaeve, European Journal of Cancer Breast OncologyCancer PathologyMedicinePathologyBreast Cancer	2007	234
Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients John A. Foekens, Maxime P. Look, Joan Bolt‐de Vries, British Journal of Cancer Prognostic BiomarkersBreast OncologyOncologyTumour ExtractsPathology	1998	204

Page 1